Abstract Library

#1286 A Comparative Analysis of Ki67 Index of the High Grade Neuroendocrine Neoplasms Arising in the Gastrointestinal Tract and the Pancreas

Introduction: A common classification has been used for NET in gastrointestinal tract (GI-NET) and pancreas (P-NET), but heterogeneity has been reported in high grade tumors; well-differentiated G3 (WDG3), poorly differentiated NEC (NEC), and mixed adenoneuroendocrine carcinoma (MANEC).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kasajima A, Ishida H, Tachibana T, Yazdani S, Sasano H,

Keywords: high grade tumors, morphological differentiation, ki-67 index,

#226 Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors

Introduction: Insulin-like growth factor-1 receptor (IGF-1R) was reported to be expressed in NET (neuroendocrine tumor) cells but its biological roles and activation status in non-functioning NET are unknown.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Sasano H, Iida S, Ono K, Nakamura Y, Miki Y,

Keywords: IGF-1R, mTOR, non-functioning neuroendocrine tumor, immunohistochemistry,

#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors

Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Atsuko K

Authors: Kasajima A, Pavel M, Darb-Esfahani S, Stenzinger A, Sasano H,

Keywords: neuroendocrine tumor, proliferation index ,

#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors

Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Sasano H

Authors: Iida S, Miki Y, Ono K, Sasano H,

Keywords: neuroendocrine tumors, mTOR inhibitors, MEK inhibitors, combination therapy,